Table 3 Univariate analysis and multivariate analysis

Sex: male/female

1.32 (0.66–2.64)

0.434

Age at operation

1.02 (0.98–1.05)

0.283

Preoperative chemotherapy (no/yes)

1.22 (0.53–2.80)

0.635

Synchronous/metachronous

1.46 (0.73–2.93)

0.288

Site of original (rectum/colon)

2.54 (1.24–5.18)

0.011

2.15 (1.15–4.93)

0.035

Histology (mucinous/adenocarcinoma)

1.53 (0.78–3.00)

0.215

Preoperative CEA level

1.00 (0.99–1.00)

0.279

Preoperative CA19-9 level

1.00 (0.99–1.00)

0.247

HIPEC regimen (lobaplatin/non-lobaplatin)

0.63 (0.31–1.28)

0.199

1.39 (0.65–2.94)

0.394

Presence of ascites (yes/no)

1.33 (0.68–2.60)

0.410

PCI score

1.09 (1.03–1.14)

0.002

1.05 (0.98–1.12)

0.140

CC score (2–3/0–1)

3.49 (1.77–6.87)

< 0.001

1.99 (1.06–4.17)

0.047

Grade 3–4 postoperative complication (no/yes)

1.63 (0.77–3.42)

0.201

Leukopenia (no/yes)

0.67 (0.28–1.63)

0.382

Neutropenia (no/yes)

0.80 (0.33–1.94)

0.626

Thrombocytopenia (no/yes)

0.49 (0.15–1.63)

0.245

BRAF status (mutation/no mutation)

1.58 (0.79–3.13)

0.266

MSI (MSS/MSI-H)

1.27 (0.61–2.73)

0.573

Adjuvant therapy (yes/no)

0.76 (0.35–1.65)

0.489

Colostomy or ileostomy (yes/no)

1.39 (0.71–2.74)

0.334